Presentation is loading. Please wait.

Presentation is loading. Please wait.

Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma.

Published byNicholas Greene Modified over 9 years ago

Similar presentations

Presentation on theme: "Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma."— Presentation transcript:

1 Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma 05/03/2010

2 CANCER OF UNKNOWN PRIMARY SITE 1.biopsy - proven malignancy; 2.histology not consistent with a primary tumor at biopsy site; 3.unrevealing history, physical examination and usual examinations 4. failure of additional diagnostic studies to identify primary site Della Porta M.G. Department of Hematology Oncology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Features:

3 From: Barry C. Lembersky, MD, and Lisa C. Thomas, MD

4 Carcinoma of Unknown Primary – Diagnosis by Light Microscopy Well differentiated adenocarcinoma (60%) Squamous cell carcinoma (5%) Poorly differentiated adenoca (15%) Poorly differentiated carcinoma (20%) From: Hainsworth J. Sarah Cannon Research Institute1 and Tennessee Oncology, PLLC,2 Nashville, Tennessee, USA

5 From: Barry C. Lembersky, MD, and Lisa C. Thomas, MD

6 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 196 ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

7 It is generally reported that unknown primary tumours account for 5–10% of all neoplasms, and that they tend to have an unfavourable prognosis Unknown Primary Tumours (ICD-O-9 codes 196–199) Survival curves for biopsy-proven (n=543) and clinically diagnosed (n=156) unknown primary malignant tumours: Vaud and Neuchatel, Switzerland, 1984–1993 (1.7%; 2.3% of all sites, excluding 173) From Levi F et al. European Journal of Cancer 38 (2002) 1810–1812

8 CART generated with the initial split on the presence or absence of liver metastases (default tree) (1000 consecutive patients with UPC) From: K.R. Hess et al. Clinical Cancer Research, Vol. 5, 3403-3410. 1999

9 Kaplan-Meier survival curves of the 10 terminal subgroups generated from the default CART analysis From: K.R. Hess et al. Clinical Cancer Research, Vol. 5, 3403-3410. 1999

10 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp ICD9CM CODE: 199 Malignant neoplasm without specification of site

11 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp ICD9CM CODE: 199 Malignant neoplasm without specification of site ICD9CM CODE: 140-208 All Malignant Neoplasms

12 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp ICD9CM CODE: 199 Malignant neoplasm without specification of site ICD9CM CODE: 140-208 All Malignant Neoplasms

13 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp ICD9CM CODE: 199 Malignant neoplasm without specification of site

14 http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp ICD9CM CODE: 199 Malignant neoplasm without specification of site

15 Lazio Region. Unknown Primary Tumours (ICD9 Code 199). N. Admissions by Hospital Typology and Year. (1) http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp Modificata ICD9CM CODE: 199 Malignant neoplasm without specification of site

16 Lazio Region. Unknown Primary Tumours (ICD9 Code 199). N. Admissions by Hospital Typology and Year. (2) http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/sceltadia.jsp Modificata ICD9CM CODE: 199 Malignant neoplasm without specification of site

17

18

19

20 ICD9CM CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

21 ICD9CM CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

22 ICD9CM CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

23 ICD9CM CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

24 ICD9CM CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplasm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

25 CODE: 196 Secondary and unspecified malignant neoplasm of lymph nodes ICD9CM CODE: 197 Secondary malignant neoplaICD9CM sm of respiratory and digestive systems ICD9CM CODE: 198 Secondary malignant neoplasm of other specified sites ICD9CM CODE: 199 Malignant neoplasm without specification of site

26 IRE. UNKNOWN PRIMARY TUMOURS. FURTHER HOSPITAL ADMISSIONS: ICD9 CODE V58 ICD9CM CODE: V580 Encounter for radiotherapy ICD9CM CODE: V581 Encounter for antineoplastic chemotherapy and immunotherapy

27 ICD9CM CODE: V580 Encounter for radiotherapy ICD9CM CODE: V581 Encounter for antineoplastic chemotherapy and immunotherapy

28 Conclusions (1) For unknown primary tumours, hospital discharge data are crucial in clinical care, especially when they are included in the framework of a hospital-based cancer registry (HCR). Even though HCR is not suitable to compute population incidence or prevalence data, it is a valid tool for hospital administration.

29 Conclusions (2)

Download ppt "Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma."

Similar presentations

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; - 35 000 cases a year; - 7.5 million population;

Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.

The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.

Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
Yao 1 Neuroendocrine Tumors James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson.

Yao 1 Neuroendocrine Tumors James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson.
9 Chapter Nine Neoplasms. © 2013 The McGraw-Hill Companies, Inc. All rights reserved. Learning Outcomes After completing this chapter, you will be able.

9 Chapter Nine Neoplasms. © 2013 The McGraw-Hill Companies, Inc. All rights reserved. Learning Outcomes After completing this chapter, you will be able.
MDS Medicare beneficiariesp-value * Overall – n7051,713,502 Age – n (%) 80 yr 67 127 272 238 (9.5) (18.0) (38.6) (33.8) 305,810.

MDS Medicare beneficiariesp-value * Overall – n7051,713,502 Age – n (%) 80 yr (9.5) (18.0) (38.6) (33.8) 305,810.
ICD-10 Getting There….. Pathology. What Physicians Need To Know Claims for ambulatory and physician services provided on or after 10/1/2015 must use ICD-10-CM.

ICD-10 Getting There….. Pathology. What Physicians Need To Know Claims for ambulatory and physician services provided on or after 10/1/2015 must use ICD-10-CM.
What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.

What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.

Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
Cancer of middle ear Chunfu Dai M.D & Ph.D. Background Primary tumor in middle cavity Primary tumor in middle cavity Predilection in 40-60 y Predilection.

Cancer of middle ear Chunfu Dai M.D & Ph.D. Background Primary tumor in middle cavity Primary tumor in middle cavity Predilection in y Predilection.
1 LUNG. 2 Equivalent Terms, Def, Charts, Tables, Illustrations.

1 LUNG. 2 Equivalent Terms, Def, Charts, Tables, Illustrations.
PRESENTING LUNG CANCER. Lung Cancer: Defined  Uncontrolled growth of malignant cells in one or both lungs and tracheo-bronchial tree  A result of repeated.

PRESENTING LUNG CANCER. Lung Cancer: Defined  Uncontrolled growth of malignant cells in one or both lungs and tracheo-bronchial tree  A result of repeated.
G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;

G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;
Chapter 28 Lung Cancer. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Objectives  Describe the epidemiology of.

Chapter 28 Lung Cancer. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Objectives  Describe the epidemiology of.
Www.siteman.wustl.edu A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Ademola Popoola,BUHARI TAJUDEEN,Fidelis Ushie,Hamid Olanipekun. Department of Surgery University of Ilorin Teaching Hospital,Ilorin. Multiple Primary Cancers.

Ademola Popoola,BUHARI TAJUDEEN,Fidelis Ushie,Hamid Olanipekun. Department of Surgery University of Ilorin Teaching Hospital,Ilorin. Multiple Primary Cancers.
Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.

Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.
The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.

The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.

Similar presentations

Ads by Google